Mira Kyivska

Amgen stock slides while oversold readings limit further downside risk

Amgen stock slides while oversold readings limit further downside risk
Amgen drops 3.22% to $443 today

Amgen (AMGN) stock is trading at $443.22, down 3.22% on the day. The price is currently positioned below its key short- and medium-term moving averages, while remaining well above longer-term trend levels.

AMGN price prediction
24H 0.03%
$443.99
48H -0.21%
$442.9
7D -0.86%
$440.03
1M 6.66%
$473.41
3M 18%
$523.74
6M 27.17%
$564.43
12M 46.63%
$650.79
Current price: $443.84 -14.0900 3.08%
Closed 11/18
Daily range 441.69 Arrow from to Icon 452.92
Weekly range 441.69 Arrow from to Icon 473.18
Loading...

Highlights

  • Amgen reported third quarter 2026 revenue of $10.4 billion, up 8% due to growth in newer therapies such as Repatha, UPLIZNA, and IMDELLTRA.
  • Shareholders of record as of November 20 will receive a $2.52 quarterly dividend per share, yielding 2.2% annualized.
  • Shares of Amgen fell 3.22% to $443.22, with technical indicators showing continued seller dominance and a projected trading range of $435.29 to $451.15.

Revenue gains from new therapies offset by legacy drug declines

Amgen reported third quarter 2026 revenue of $10.4 billion, an 8% increase driven by growth in newer therapies such as Repatha, UPLIZNA, and IMDELLTRA, with higher R&D expenditures, according to Yahoo Finance. The improved revenue mix reflects a successful transition toward innovative products, offsetting declines in legacy drugs and supporting ongoing cash generation. In addition, the company will pay shareholders of record as of November 20 a quarterly dividend of $2.52 per share, representing a 2.2% annualized yield, as reported by Defenseworld, though price action has remained under broader selling pressure.

Amgen asset chart
Amgen price dynamics. Source: TradingView.

Immediate resistance and seller momentum as rebound risk rises

On the technical front, AMGN is trading below the H1 SMA-20 at $462.91 and H1 SMA-50 at $464.29, while remaining well above the D1 SMA-200 at $382.17. The Ichimoku Kijun at $461.44 defines immediate resistance for further upside attempts. Momentum indicators remain negative: MACD and ADX indicate selling pressure, while Bull/Bear Power stands at –4.49, confirming seller dominance intraday. Meanwhile, RSI, Stochastic RSI, and CCI are all in the oversold zone, suggesting short-term selling exhaustion and elevated risk of a near-term rebound. The Awesome Oscillator continues to support the current downtrend.

Further downside risk as sellers control near-term trading range

Looking ahead, AMGN is expected to consolidate within a typical volatility band between support at $435.29 and resistance at $451.15 in the near term. The likelihood of a further move downward is high, with a potential rebound remaining less probable as sellers retain control. A bullish scenario would require a break above immediate resistance at $461.44 to trigger renewed buying interest, while a loss of support at $435.29 could open the way for further declines.

Anton Kharitonov, expert at Traders Union, notes that Amgen’s Q3 2026 results confirm stable underlying fundamentals, but the stock’s technical picture remains weak. He sees price capped below both the H1 SMA-20 at $462.91 and H1 SMA-50 at $464.29, with momentum indicators confirming downside pressure despite oversold signals. The analyst believes a further drop is likely unless immediate resistance is reclaimed. "Base case is continued consolidation and risk of new lows while sellers control the tape — a technical recovery needs a decisive break above $461.44."

Previously it was reported that Amgen’s technical setup remained broadly constructive, supported by clinical trial progress and robust business fundamentals. The current retracement below short- and medium-term moving averages, despite ongoing revenue growth and new product momentum, shifts near-term focus to support at $435.29 as a critical level for downside risk monitoring.

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.